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ings in most scenarios, the variation of IFX vial and ADA syringe costs are important 
factors that could modify the sensitivity analysis. ConClusions: The treatment 
of Crohn’s disease with ADA compared to IFX presented an economic savings for 
nearly 68% of patients with Crohn’s Disease in the Brazilian Private HealthCare 
System.
PSY67
CoSt-EffECtivEnESS ModElling for nEuroPathiC Pain trEatMEntS: 
an ExPloration to idEntifY CoMParativE iMPortanCE of ModEl 
ParaMEtErS
Critchlow S1, Hirst M2, Sullivan W1, Dunlop W2
1BresMed Health Solutions, Sheffield, UK, 2Mundipharma International Ltd, Cambridge, UK
objeCtives: To provide an open-access model and illustrate how this can be used 
as a first step in the early economic evaluation of emerging neuropathic pain 
products, enabling the understanding of important parameters in the assess-
ment of therapies. Methods: We closely replicated a model structure created 
by NICE to inform guideline development in neuropathic pain. The structure was 
replicated as R code for ease of exposition. Costs were updated to reflect 2014 
prices. The exploratory analysis considered a hypothetical drug ‘Product X’ versus 
pregabalin, a product used widely in neuropathic pain. The analysis explored the 
percentage premium over the price of pregabalin that would result in an ICER at 
the NICE threshold of £20,000 when varying efficacy parameters. Results: A 30% 
improvement over pregabalin in the proportion of patients achieving a 30-49% 
reduction in pain could justify a price premium of 39%, whilst a 30% improve-
ment in the proportion of patients achieving ≥ 50% improvement could justify a 
premium of 170%. If ‘Product X’ provides no analgesic improvement but causes 
30% fewer adverse events and related withdrawals, a premium of 27% could be 
justified. ConClusions: The analyses presented highlight how this transpar-
ent model can be used as a tool for identifying parameters of importance in the 
early economic evaluation in neuropathic pain. The R code underpinning these 
analyses is made readily available and we welcome the ISPOR community to 
use, adapt and provide comments on how to refine and improve this model for 
future use.
PSY68
CoSt-utilitY analYSiS of adaliMuMab for thE trEatMEnt of 
ModEratE-to-SEvErE ulCErativE ColitiS in PatiEntS in SPain
Wang S1, Yang H2, Yang M2, Bao Y1
1AbbVie Inc., North Chicago, IL, USA, 2Analysis Group, Inc., Boston, MA, USA
objeCtives: Treatments for patients with moderate-to-severe ulcerative coli-
tis (UC) include biologic (adalimumab [ADA], infliximab [IFX], and golimumab 
[GOL]) and non-biologic therapies (anti-inflammatory drugs and immunosup-
pressants). Non-biologic therapy is standard of care (SOC). We evaluated the 
cost utility of ADA+SOC vs SOC alone and assessed the total cost difference 
of ADA+SOC vs IFX+SOC and GOL+SOC for treating moderate-to-severe UC in 
patients with inadequate response to non-biologic therapy in Spain. Methods: 
A Markov model was developed to simulate treatment and disease progression 
for UC patients, which considered 8 health states: 3 pre-surgery (remission, mild, 
and moderate-to-severe), surgery, and 4 post-surgery (no complication, transient 
complication, chronic complication, and death). The model assumed no differ-
ence in efficacy of biologic therapies. Transitional probabilities of pre-surgery, 
surgery and post-surgery states were derived from clinical trials of ADA and 
published literature. Health utility and cost inputs came from literature. Only 
direct costs were considered in the base case. Results were expressed in costs 
per quality-adjusted life-year (QALY) gained for ADA+SOC vs SOC alone and 
total cost differences for ADA+SOC vs IFX+SOC and GOL+SOC. Deterministic 
and probabilistic sensitivity analyses (DSA, PSA) were performed. Results: 
The incremental costs per QALY gained for ADA+SOC vs SOC alone were € 46,815 
over a 10-year time horizon (2013 euro). Results from DSA ranged from € 33,622 
(when indirect costs were considered) to € 49,083 (when the utilities of health 
states were changed). PSA revealed that ADA+SOC was cost-effective in 61% and 
84% of the simulations at € 50,000/QALY and € 60,000/QALY thresholds, respec-
tively. Compared with IFX+SOC and GOL+SOC, ADA+SOC was associated with 
cost savings of € 8,570 and € 37,113, respectively. DSA and PSA results showed 
that ADA+SOC led to cost savings in all scenarios. ConClusions: For UC, the 
ADA+SOC strategy demonstrated reasonable cost-effectiveness value compared 
with SOC alone and was cost-saving compared with IFX+SOC and GOL+SOC, in 
Spain.
PSY69
CoSt-utilitY of bariatriC SurgErY in bElgiuM, dEnMark, and italY
Borisenko O1, Burdukova E1, Hargreaves J2, Adam D1, Funch-Jensen P3
1Synergus AB, Stockholm, Sweden, 2Covidien (UK) Commercial Ltd, now part of Medtronic, 
Hampshire, UK, 3Aarhus University, and Aleris Hamlet Hospital, Aarhus, Denmark
objeCtives: To evaluate the cost-utility of bariatric surgery in Belgium, Denmark, 
and Italy from a third-party payer perspective over a 10-year and a lifetime hori-
zon. Methods: A state-transition Markov model was developed, in which patients 
may experience surgery, post-surgery complications, diabetes mellitus type 2, car-
diovascular diseases or die. Transition probabilities, surgery effectiveness and safety, 
costs, and utilities were informed by the literature, patient registries and adminis-
trative databases. Three types of surgeries were considered: gastric bypass, sleeve 
gastrectomy, and adjustable gastric banding. A base-case analysis was performed for 
the population of real surgical candidates in all countries. Cost data are presented 
in 2012 euros for Belgium, Italy and Denmark. Results: In Belgium, in the base-
case analysis over 10 years bariatric surgery led to incremental cost of € 3,261 and 
generated additional 1.4 quality-adjusted life years (QALYs) with incremental cost-
effectiveness ratio of € 2,407/QALY. Over lifetime, surgery led to savings of € 10,036, 
and generated additional 1.1 years of life, and 5.0 QALYs. In Denmark, in the base-
case analysis over 10 years bariatric surgery led to incremental cost of € 2,044 and 
PSY64
CoSt-EffECtivEnESS analYSiS of PrEgabalin in thE trEatMEnt of 
CEntral nEuroPathiC Pain
Karbusicka M1, Kolek M1, Duba J1, Vothova P2, Dolec kova J1
1OAKS Consulting s.r.o., Prague 9, Czech Republic, 2Pfizer, spol. s r. o., Prague 5, Czech Republic
objeCtives: To compare costs and effectiveness of pregabalin compared to pla-
cebo in the treatment of central neuropathic pain (CNP) from the perspective of 
the public healthcare payer in the Czech Republic. Methods: A de novo micro-
simulation model was developed in MS Excel comparing pregabalin treatment of 
CNP versus placebo as there is no other treatment of CNP available and reimbursed 
in the Czech Republic. The improvement of patients’ pain intensity expressed 
as the decrease in VAS (Visual Analog Scale (0-100) score was modelled during 
the 24 week time horizon. The changes of VAS score were estimated for each 
intervention using a regression functions of time and the baseline VAS score. 
Utilities were assigned to each VAS score according to the regression equations 
expressing the dependence of utility value on average weekly VAS score of CNP 
patients. Relevant costs (reflecting payer’s perspective) were defined as costs of 
pharmacotherapies, outpatient care related to drug application, management of 
treatment, treatment of adverse events and concomitant medication were con-
sidered. Results: The incremental cost-effectiveness ratio (ICER) of pregabalin 
compared to placebo reached 8,335.22 EUR per Qualy-adjusted-life-year (QALY) 
gained. The probability of pregabalin being cost-effective (ICER under willing-
ness to pay 39,876.74 EUR) was 100%. ConClusions: Pregabalin is the only 
option for the treatment of CNP in the Czech Republic and brings significant pain 
relief for patients. Treatment with pregabalin also results in low ICER and can be 
considered a cost-effective treatment of central neuropathic pain in the Czech 
Republic.
PSY65
CoSt-EffECtivEnESS of uStEkinuMab in thE trEatMEnt of PSoriaSiS in 
finland
Väätäinen S1, Soini EJ1, Valgardsson VS2, Mälkönen T3
1ESIOR Oy, Kuopio, Finland, 2Janssen-Cilag AS, Oslo, Norway, 3Helsinki University Hospital, Skin 
and Allergy Hospital, Helsinki, Finland
objeCtives: To evaluate the cost-effectiveness of ustekinumab in the treatment 
of psoriasis in the Finnish setting. Methods: A sequential Markov cohort model 
was programmed in Excel using Visual Basic for Applications. First, the most 
frequently used treatment sequence (ustekinumab -> adalimumab -> etaner-
cept -> infliximab -> maintenance, Finnish “current care”) was compared to the 
most used sequence prior to ustekinumab’s market authorization (adalimumab 
-> etenarcept -> infliximab -> maintenance, “past care” in Finland) in a con-
firmatory analysis setting. Then the incremental cost-effectiveness of all relevant 
treatment sequences was explored to find out the health economic relevance 
of current and past care sequences. The primary analysis outcomes were direct 
payer costs and quality-adjusted life years (QALY) gained. Secondary outcomes 
included Psoriasis Area and Severity Index (PASI) response years gained and 
Dermatology Quality of Life Index (DLQI) years avoided. Drugs, follow-up, drug 
administration, laboratory tests, adverse events and treatment failures as well 
as direct costs to patient were included as costs at 2014 price level. Initial treat-
ment efficacy was based on a Bayesian network meta-analysis of randomized 
clinical trials, and treatment persistence was modeled based on recent real 
world registry studies. All results were discounted with 3% per annum during 
the 5-year modelling timeframe. Results: The total discounted 5-year costs 
were € 74,383 for the current care and € 76,847 for the past care sequence. The 
respective QALYs were 3.895 and 3.825. Thus, the current care using ustekinumab 
dominated the past care without ustekinumab. PASI and DLQI results were in 
line with QALY results. Results were robust in the performed sensitivity analy-
ses. Furthermore, in the explorative analysis of all relevant treatment sequences, 
ustekinumab was always part of the cheapest sequence. ConClusions: 
Ustekinumab is the most cost-effective treatment in the current Finnish pso-
riasis treatment practice, and its use is both clinically and health economically 
relevant.
PSY66
CoSt-MiniMization analYSiS and total CoSt analYSiS for a WEight 
rangE in Crohn’S diSEaSE trEatMEnt With anti-tnf biologiCS undEr 
brazilian PrivatE hEalth CarE SYStEM PErSPECtivE
Menezes FG, Chibana V
AbbVie Brazil, São Paulo, Brazil
objeCtives: The aim of this study was to describe the total treatment costs related 
to Crohn’s Disease treatment with biologics and to evaluate these costs based on 
the most prevalent weight range. Methods: A cost-minimization analysis was 
performed among adalimumab-subcutaneous (ADA) and infliximab-intravenous 
(IFX) to compare the total treatment costs in Crohn’s disease according to the 
Brazilian Private HealthCare System perspective. Total treatment cost was calcu-
lated based on the dose per application, number of vial/syringe, cost of application 
and median and range of weight. These inputs were based on scientific literature. 
Yearly treatment cost was calculated for patients with a median of 68kg, according 
to doses defined in product labels. A cost analysis for a weight range was per-
formed. Drug prices were based on Factory Prices plus 18% taxes (CMED source). An 
univariate analysis was performed to determine the impact on results. Results: 
The median patient weight used in this analysis was 68±4,08kg (Weight range: 
64 to 72kg - normal distribution). For IFX the Medication Cost was R$92.478,12, 
Application Cost was R$2.360,33 and the Total Treatment Cost was R$94.838,45. For 
ADA the Medication Cost was R$85.807,15, Application Cost was R$3.788,98 and the 
Total Treatment Cost was R$89.596,13. Comparing the scenario with IFX and ADA, 
the treatment with ADA presented a savings of R$5.242,32 per patient/year. The 
weight interval cost analysis presented a savings for ADA of R$5.242,32 per patient/
year in a range of 64 to 72kg. In sensitivity analysis ADA presented economic sav-
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internally and externally validated, the deterministic and probabilistic sensitivity 
analyses were performed to evaluate uncertainty. A base-case analysis was per-
formed for the population of real surgical candidates in both countries. Cost data 
are presented in 2012 euros. Results: In Germany, in the base-case analysis over 
10 years bariatric surgery led to incremental cost of € 2,909 and generated additional 
0.03 years of life and 1.2 quality-adjusted life years (QALYs) with incremental cost-
effectiveness ratio of € 2,457/QALY. Over lifetime, surgery led to savings of € 8,522, 
and generated additional 0.7 years of life, and 3.2 QALYs. In France, in the base-case 
analysis over 10 years bariatric surgery led to incremental cost of € 1,106 and gener-
ated additional 1.3 QALYs with incremental cost-effectiveness ratio of € 852/QALY. 
Over lifetime surgery lead to savings of € 8,359, additional 0.5 life years, and 3.4 
QALYs. In both countries surgery was also associated with reduction of incidence 
of diabetes and cardiovascular disorders. One- to three-year delay in provision of 
surgery led to reduction of clinical effectiveness, but had diverse impact on total cost 
in different patient cohorts. ConClusions: In a comprehensive decision analytic 
model, a current mix of surgical methods for bariatric surgery was cost-effective 
at 10 years and cost saving over the lifetime time horizon in Germany and France.
PSY73
CoSt-EffECtivEnESS of bariatriC SurgErY for thE trEatMEnt of 
obESitY in auStralia
Salton R
Center for Applied Health Economics, Brisbane, Australia
objeCtives: Obesity is on the rise globally, especially in developed countries and 
Australia is no exception. Currently, the most effective treatment for sustainable 
weight loss is bariatric surgery. This study is the first of its kind to assess the 
cost-effectiveness of 3 bariatric surgery procedures in comparison with standard 
care in Australia. Methods: A decision analytic model incorporating Markov 
process will be undertaken to compare adjustable gastric banding (AGB), Roux-
en-Y Bypass (RYGB) and sleeve gastrectomy (SG) against standard care. The states 
will be based on BMI categories obtained from WHO and NICE guidelines. The 
cycle length will be one year and, owing to the limited availability of long-term 
data for bariatric procedures, the model will have a time horizon of 10 years. 
Utilities will be based on the SF-6D and transition probabilities will be derived 
from a network meta-analysis of BMI reductions as the treatment effect for the 
various comparators. Cost data will be obtained from the Australian Institute 
of Health and Welfare (AIHW). Construction of the model will be carried out via 
Microsoft Excel and the results will be presented as a comparison of costs and 
quality-adjusted-life years (QALYs) to generate ICERs for each of the interven-
tions. One-way sensitivity analysis in addition to PSA will be carried out to test 
the robustness of the model in terms of the assumptions made and various input 
parameters. Results: Construction of the model has already commenced and 
will be finished by mid-July; full completion of the write-up will be completed by 
the end of July. This research is carried out in conjunction between City University 
London and Griffiths University (Brisbane, Australia). ConClusions: To be com-
pleted by 15/07/2015.
PSY74
CoSt–utilitY analYSiS of antihEMoPhiliC faCtor rfviii-fS 
for SECondarY ProPhYlaxiS vS on-dEMand thEraPY in SEvErE 
haEMoPhilia a in italY
Tagliaferri A1, Coppola A1, Amoresano S2, Aiello A3, D’Ausilio A3, Toumi M4
1Reference Centre for Coagulation Disorders, Napoli, Italy, 2Bayer Healthcare, Milano, Italy, 
3Creativ Ceutical, Milano, Italy, 4Aix-Marseille University, Marseille, France
objeCtives: Haemophilia A causes a considerable burden on society. While prophy-
laxis in children aged ≤ 2y is now a gold standard treatment, the benefits of late 
secondary prophylaxis are still controversial. Aim of this study is to estimate the 
cost-utility of antihemophilic factor rFVIII-FS (Kogenate® FS) in secondary prophy-
laxis vs on-demand regimen from the Italian healthcare system (NHS) and society 
perspective. Methods: An individual patient simulation model was adapted to 
estimate the costs and outcomes associated with secondary prophylaxis and on-
demand treatment. The model follows a hypothetical cohort of 1000 patients in a 
lifetime period. The POTTER observational study represented the source for clinical 
data such as clothing factors regimens and consumption, adherence to prophylaxis, 
risk of joint and total bleeds, quality-of-life (QOL) scores and productivity loss. For 
other data such as intracranial haemorrhage and major surgery rate, data from 
published literature were used. Drugs costs were estimated using prices reimbursed 
by the NHS while hospital costs were estimated with national hospital (inpatient 
and outpatient) tariffs. Caregivers’ or patients’ productivity loss was estimated with 
Italian daily Gross Net Product per-capita. Costs and benefits were discounted at 
6.0% in line with published economic evaluations on this subject. Incremental 
cost-effectiveness ratios (ICERs) were calculated. Model outcomes are expressed 
in terms of costs per quality-adjusted-life-years (QALY). Results: As expected, 
mean lifetime costs are higher with secondary prophylaxis than with on-demand 
treatment. Secondary prophylaxis however determines better outcomes in bleed-
ing reduction and better QoL. Using the NHS perspective (considering only direct 
healthcare costs) secondary prophylaxis shows an ICER vs on-demand of € 51,202/
QALY; a more favourable ICER of € 45,432/QALY is shown when considering also indi-
rect costs. ConClusions: Despite the high cost of the pharmacological treatment, 
antihemophilic factor rFVIII-FS in secondary prophylaxis represents a cost-effective 
approach compared with on-demand treatment.
PSY75
EConoMiC Evaluation of daSatYnib in trEatMEnt of adult PatiEntS 
With PhiladElPhia ChroMoSoME PoSitivE (Ph+) aCutE lYMbPhoblaStiC 
lEukEMia (all) With rESiStanCE or intolEranCE to Prior thEraPY in 
Poland
Mucha J1, Stelmachowski J1, Walczak J1, Pieniazek I1, Obrzut G1, Labak-Klimasara M2
1Arcana Institute Ltd, Krakow, Poland, 2Bristol-Myers Squibb Services Sp. z o.o., Warsaw, Poland
generated additional 1.5 QALYs with incremental cost-effectiveness ratio of € 1,405 
per QALY. Over lifetime surgery lead to savings of € 5,032, additional 0.8 life years, 
and 4.1 QALYs. In Italy, in the base-case analysis over 10 years bariatric surgery led 
to incremental cost of € 2,552 and generated additional 1.1 QALYs with incremen-
tal cost-effectiveness ratio of € 2,314/QALY. Over lifetime, surgery led to savings of 
€ 8,874, and generated additional 0.5 years of life, and 3.2 QALYs. ConClusions: 
In a comprehensive decision analytic model, a current mix of surgical methods for 
bariatric surgery was cost-effective at 10 years and cost saving over the lifetime 
time horizon in three European countries.
PSY70
CoSt-EffECtivEnESS and CoSt-utilitY analYSES CoMParing StratEgiES 
for initial trEatMEnt of rhEuMatoid arthritiS uSing PubliShEd 
outCoMES: EConoMiC lESSonS froM thE tEar trial
Fuchs PA1, Lal L2, Fuchs HA3, Swint J4
1University of Texas Medical School at Houston, Houston, TX, USA, 2Cardinal Health, Missouri 
City, TX, USA, 3Vanderbilt University Medical Center, Nashville, TN, USA, 4University of Texas 
School of Public Health, Houston, TX, USA
objeCtives: Controversy surrounds the most appropriate initial treatment regimen 
for Rheumatoid Arthritis. The objective of the present study is to aid in this debate 
by providing cost-effectiveness and cost-utility analyses for four treatment scenar-
ios. Methods: Estimates of costs were applied to outcome data from the Treatment 
of Early Aggressive Rheumatoid Arthritis (TEAR) Trial to determine cost-effective-
ness. Treatment regimens from the TEAR trial, immediate etanercept (IE), immediate 
triple therapy (methotrexate, sulfasalazine, and hydroxychloroquine) (IT), step-up 
etanercept (SE), and step-up triple therapy (ST), were compared. Each regimen used 
methotrexate as a background medication. Outcomes analyzed include Disease 
Activity Scores (DAS-28-ESR) from the TEAR trial, calculated Clinical Disease Activity 
Index (CDAI) scores, and Quality-adjusted Life Years (QALYs) calculated using lit-
erature estimates. Discontinuers were assigned cost and outcome estimates based 
on duration of participation and associated outcomes. Analysis was limited to the 
two year time horizon of the TEAR trial. Results: ST was cost-effective for all 
outcome measures, and had the highest net monetary benefit (NMB) for DAS-28-
ESR ($592,569) and QALYs ($71,080), using a willingness to pay (WTP) of $250,000. 
IE was dominated for CDAI and had the lowest NMBs for DAS-28-ESR and QALYs, 
with incremental cost-effectiveness ratios (ICERs) of $1,025,534 and $8,205,670, 
respectively. SE was dominated for all outcomes. Results from one-way and proba-
bilistic sensitivity analysis were consistent with these findings. ConClusions: 
The treatment strategies using etanercept were more costly than triple therapy 
strategies, with similar outcomes and ICERs outside most acceptable levels. SE was 
not cost-effective for any outcome, and ST was a consistently cost-effective treat-
ment strategy.
PSY71
CoSt-EffECtivEnESS analYSiS of toCilizuMab SubCutanEouS aS firSt 
linE biologiC MonothEraPY for rhEuMatoid arthritiS ManagEMEnt 
in grEECE
Athanasakis K1, Tarantilis F1, Skroumpelos A2, Kyriopoulos J1
1National School of Public Health, Athens, Greece, 2Roche (Hellas) S.A., Athens, UK
objeCtives: Rheumatoid Arthritis (RA) is a chronic, inflammatory disease, affecting 
0.68% of adult population in Greece. RA is associated with decreased quality of life 
and a significant economic burden. The intravenous (IV) formulation of Tocilizumab 
(TCZ) has already proven its efficiency and thus the aim of this study is to evaluate 
and confirm the cost-effectiveness of the subcutaneous (SC) formulation as first line 
biologic monotherapy. Methods: Lifetime costs and outcomes for 10,000 patients 
were projected through an individual simulation model. The analysis compared a 
standard treatment pathway (STP) (Adalimumab, Etanercept and Palliative care) with 
a similar pathway where treatment was initiated with TCZ SC. Health Assessment 
Questionnaire (HAQ) scores were used to reflect disease severity. The primary efficacy 
outcome considered was American College of Rheumatology (ACR) response. Patient 
baseline characteristics derived from the ADACTA trial. Efficacy data were elicited 
from a network meta-analysis. A mapping model transformed HAQ scores into QALYs. 
Clinical practice standards were determined by Expert Opinion (12 Rheumatologists). 
Costs for pharmaceuticals and unit costs for resources were obtained from official 
price lists. Estimated mandatory rebates for new products were taken into account. 
A third-party payer (Social Insurance) perspective was employed. Costs and QALYs 
were discounted at 3%. Results: The treatment sequence starting with TCZ SC 
yielded 0.98 more QALYs (9.08vs. 8.10) at an additional cost of € 27,442.5 (€ 132,733.78 
vs. € 105,291.27) compared to the STP.The Incremental Cost – Effectiveness Ratio (ICER) 
was estimated at € 27,974.28 per QALY gained which is below the national commonly 
used threshold. Probabilistic Sensitivity Analysis confirms robustness of findings 
below a threshold of € 45,000. ConClusions: The results of the analysis suggest that 
TCZ SC can be a cost-effective alternative and provide both patients and health care 
system with more options for RA management due to dual formulation’s effective-
ness and efficiency.
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CoSt-utilitY of bariatriC SurgErY in franCE and gErManY
Borisenko O1, Burdukova E1, Hargreaves J2, Adam D1
1Synergus AB, Stockholm, Sweden, 2Covidien (UK) Commercial Ltd, now part of Medtronic, 
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objeCtives: To evaluate the cost-utility of bariatric surgery in Germany and France 
from a third-party payer perspective over a mid-term (10 years) and a long-term (life-
time) horizon. Methods: A state-transition Markov model was developed, in which 
patients may experience surgery, post-surgery complications, diabetes mellitus type 
2, cardiovascular diseases or die. Transition probabilities, data about effectiveness 
and safety of surgery, costs, and utilities were informed by the literature, patient 
registries and administrative databases. Three types of surgeries were considered: 
gastric bypass, sleeve gastrectomy, and adjustable gastric banding. The model was 
